BCLI Brainstorm Cell Therapeutics In

4.09
0  -1%
Previous Close 4.12
Open 4.17
Price To book 7.77
Market Cap 76.43M
Shares 18,687,000
Volume 156,111
Short Ratio 3.17
Av. Daily Volume 270,605

SEC filingsSee all SEC filings

  1. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17722237
  2. 8-K - Current report 17668045
  3. 8-K - Current report 17657080
  4. 8-K - Current report 162057741
  5. 8-K - Current report 162042869

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released July 2016. Phase 3 trial to be initiated 2Q 2017.
NurOwn
Amytrophic lateral sclerosis (ALS)

Latest News

  1. BrainStorm Announces Publication of NurOwn® Autism Research Study
  2. Today's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals
  3. BrainStorm Announces Financial Results for 2016 and Provides Business Update
  4. BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
  5. Israel's BrainStorm names Biogen senior executive Kern as COO
  6. BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
  7. BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product
  8. BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
  9. BCLI: Seeking Early Regulatory Approval in Canada for NurOwn® in ALS
  10. Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics
  11. BrainStorm Seeks ALS Drug Approval In Canada
  12. BrainStorm Seeking Approval To Distribute NurOwn® in Canada
  13. BrainStorm seeks early approval for stem cell treatment in Canada
  14. City of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial
  15. BrainStorm CEO to Present at the BIO CEO & Investor Conference
  16. BrainStorm Announces Validation of NurOwn® Cryopreservation Process
  17. The Life Sciences Report Asks If It Is Time to Go Long on BrainStorm Cell Therapeutics
  18. BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami

SEC Filings

  1. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17722237
  2. 8-K - Current report 17668045
  3. 8-K - Current report 17657080
  4. 8-K - Current report 162057741
  5. 8-K - Current report 162042869
  6. 8-K - Current report 162032594
  7. EFFECT - Notice of Effectiveness 162011652
  8. 10-Q - Quarterly report (Sections 13 or 15(d)) 161996490
  9. POS AM - Post-Effective amendments for registration statement 161996425
  10. S-8 - Securities to be offered to employees in employee benefit plans 161894353